Changing fortunes: is Biotech giant CSL’s $10 billion write-down a comeback story?
Make no mistake: the home-grown biotechnology company, which for decades allowed Australia serious boasting rights, is still a long way from redemption.
We haven't written up this one. The Sydney Morning Herald has the full story — the link below goes straight to it.